Shares jump amid compelling Phase 3 readout
Amylyx Pharmaceuticals shares climbed sharply in mid-day trading, gaining 48.6% after the company disclosed Phase 3 results for avexitide, its lead investigational therapy for post-bariatric hypoglycemia (PBH). The data come from the LUCIDITY trial, a 78-participant, multicenter, randomized, double-blind, placebo-controlled study that was conducted under parameters agreed with the FDA.
Trial outcomes and safety profile
The LUCIDITY study met its primary endpoint, showing a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events versus placebo. The result was supported by an exceptionally strong p-value of 0.000003. According to the company, all secondary endpoints were also met, with clinically meaningful reductions reported across multiple measures of hypoglycemic burden. Avexitide was described as generally well-tolerated, with a favorable safety profile noted in the announcement.
Market reaction and lead-up
The rally began the previous evening when shares jumped about 14.5% in after-hours trading after Amylyx said the LUCIDITY results would be released the following morning, tightening its earlier guidance that had pointed to a broader third-quarter 2026 window. The intraday surge pushed AMLX to a 52-week intraday high of $32.81, which the company noted was its highest level within the past year.
Analyst response and commercial assumptions
Adding to the market momentum, Mizuho analyst Graig Suvannavejh raised his price target on AMLX to $30 from $24 while keeping an Outperform rating and naming the stock a top pick ahead of the data readout. The analyst’s revision incorporated higher launch pricing assumptions for avexitide, a factor cited in the analyst note accompanying the upgrade.
Regulatory pathway and launch timing
Amylyx confirmed plans to submit a New Drug Application to the FDA by year-end 2026 and said preparations are underway for a potential commercial launch of avexitide in 2027. The company framed that regulatory timeline as credible, citing avexitide’s FDA Breakthrough Therapy Designation and Orphan Drug Designation for the PBH indication.
Broader market context
The stock’s dramatic outperformance was notable given a wider market slide on the same day: the S&P 500 declined about 0.5%, the Dow Jones slipped roughly 0.2%, and the NASDAQ fell near 1.1%. Those declines underscore that AMLX’s move was driven by company-specific catalysts rather than favorable macro conditions.
Commercial significance
Post-bariatric hypoglycemia currently has no approved treatment options, a factor the company highlighted in discussing the potential commercial opportunity. A successful NDA submission and approval could position avexitide as a first-in-class, first-approved therapy for an underserved patient population, according to the announcement.
What to watch next
Key upcoming items for investors include the company’s formal submission of an NDA by the end of 2026 and execution of its stated planning for a 2027 commercial launch. Market participants will also be watching how regulatory review progresses and whether the company’s pricing and launch assumptions are borne out as plans move forward.